When Did OxyContin's Patents Expire?
Purdue Pharma's original OxyContin patents expired in 2013, clearing the way for generic oxycodone extended-release (ER) formulations.[1] Key patents like US 5,656,065 (covering controlled-release oxycodone) ended then, though Purdue held pediatric exclusivity until August 2013 and faced ongoing litigation over abuse-deterrent versions.
Which Generic Manufacturers Stepped In?
Teva Pharmaceuticals launched the first authorized generic OxyContin in August 2013, matching Purdue's original formulation.[1][2] Other FDA-approved generics followed from:
- Impax Laboratories (now Amneal)
- Mallinckrodt
- Purdue itself (via authorized generics)
- Actavis (now Teva)
- Watson (now Teva)
These are AB-rated equivalents, bioequivalent to brand OxyContin (oxycodone HCl ER tablets).[3]
What About Abuse-Deterrent Generics?
Purdue's reformulated OxyContin (OP, approved 2010) has crush-resistant patents expiring in 2027-2030, depending on the claim.[1] No generics match this version yet—FDA requires proving abuse-deterrent properties for interchangeability. In 2023, Dr. Reddy's filed an ANDA for a generic OP, but approval awaits patent settlements or challenges.[1]
Availability and Pricing Today
Generics dominate the market, accounting for over 90% of oxycodone ER prescriptions.[4] A 30-day supply of 30mg generic costs $20-100 at retail (vs. $400+ for brand), varying by pharmacy and insurance.[5] Check GoodRx or Drugs.com for local prices.
Access Restrictions and Risks
DEA Schedule II controls limit generics to pain management with risk evaluation (REMS program).[3] Patients report shortages occasionally due to manufacturing issues or quotas.[6] Common concerns include addiction risk—generics carry the same black-box warning for misuse as the brand.
How Do Generics Compare to OxyContin?
| Feature | Brand OxyContin (Original) | Authorized Generic (e.g., Teva) | Abuse-Deterrent OxyContin (OP) |
|---------|----------------------------|---------------------------------|--------------------------------|
| Formulation | Standard ER oxycodone | Identical | Crush-resistant polymer |
| Cost | High | 70-90% less | High (generics pending) |
| Availability | Limited | Widely stocked | Brand-only until ~2027+ |
| Interchangeable | N/A | Yes (AB-rated) | No generics yet |
Switching requires doctor oversight due to potency risks.[3]
[1]: DrugPatentWatch.com - OxyContin Patents
[2]: FDA Orange Book - Oxycodone ER Approvals
[3]: FDA REMS for Opioids
[4]: IQVIA Market Data 2023
[5]: GoodRx - Oxycodone ER Pricing
[6]: FDA Drug Shortages Database